Supplementary Materials

Supplementary Material for:

Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL

Scott McComb, Júlia Aguadé-Gorgorió, Lena Harder, Blerim Marovca, Gunnar Cario, Cornelia Eckert, Martin Schrappe, Martin Stanulla, Arend von Stackelberg, Jean-Pierre Bourquin, Beat C. Bornhauser*

*Corresponding author. Email: beat.bornhauser{at}kispi.uzh.ch

Published 18 May 2016, Sci. Transl. Med. 8, 339ra70 (2016)
DOI: 10.1126/scitranslmed.aad2986

This PDF file includes:

  • Materials and Methods
  • Fig. S1. ALL patient samples are sensitive to LCL161 in vitro but not in vivo.
  • Fig. S2. TNF blocking effectively rescues TNF-dependent sensitization to birinapant.
  • Fig. S3. Birinapant induces dual activation of apoptosis and necroptosis in ALL cell lines.
  • Fig. S4. In vivo birinapant treatment selects CRISPR-driven RIP1-deficient cells.
  • Fig. S5. RIP1 is not required for response to a wide range of chemotherapeutic agents.
  • Table S1. Patient characteristics.
  • Table S2. sgRNA-targeting sequences used for gene disruptions.

[Download PDF]